Identification of a broad coverage HLA-DR degenerate epitope pool derived from carcinoembryonic antigen

Cancer Immunology, Immunotherapy

Volumn 59, Issue 1, 2010, Pages 161-171

  Karyampudi, Lavakumar ^a   Krco, Christopher J ^a   Kalli, Kimberly R ^b   Erskine, Courtney L ^a   Hartmann, Lynn C ^b   Goodman, Karin ^b   Ingle, James N ^b   Maurer, Matthew J ^b   Nassar, Aziza ^b   Yu, Chao ^a   Disis, Mary L ^c   Wettstein, Peter J ^a   Fikes, John D ^d,e   Beebe, Melanie ^d   Ishioka, Glenn ^d,f   Knutson, Keith L ^a  

^a MAYO GRADUATE SCHOOL   (United States)

^b MAYO CLINIC   (United States)

^c Center for Translational Medicine in Women's Health   (United States)

^d Epimmune   (United States)

^e Kalypsys Inc   (United States)

^f NONE   (United States)

Author keywords

Helper T cells; HLA DR; MHC class II; Peptides; Vaccines

Indexed keywords

AMINO ACID; CARCINOEMBRYONIC ANTIGEN; EPITOPE; GAMMA INTERFERON; HLA DR ANTIGEN;

ADULT; AMINO ACID SEQUENCE; ANTIGEN PRESENTING CELL; ARTICLE; BINDING AFFINITY; BREAST CANCER; CD4+ T LYMPHOCYTE; CELLULAR IMMUNITY; CLINICAL ARTICLE; CONTROLLED STUDY; ENZYME LINKED IMMUNOSPOT ASSAY; HUMAN; HUMAN TISSUE; LYMPHOCYTE PROLIFERATION; MALE; OVARY CANCER; PRIORITY JOURNAL; TUMOR IMMUNITY;

ADULT; BREAST NEOPLASMS; CARCINOEMBRYONIC ANTIGEN; CD4-POSITIVE T-LYMPHOCYTES; EPITOPES; FEMALE; HLA-DR ANTIGENS; HUMANS; MIDDLE AGED; OVARIAN NEOPLASMS; SOFTWARE;

EID: 70350113820     PISSN: 03407004     EISSN: 14320851     Source Type: Journal    
DOI: 10.1007/s00262-009-0738-z     Document Type: Article

References (43)

1. C Yee JA Thompson D Byrd SR Riddell P Roche E Celis PD Greenberg 2002 Adoptive T cell therapy using antigen-specific CD8+ T cell clones for the treatment of patients with metastatic melanoma: in vivo persistence, migration, and antitumor effect of transferred T cells Proc Natl Acad Sci USA 99 16168 16173 10.1073/pnas.242600099 12427970 1:CAS:528:DC%2BD38Xps1ensLk%3D (Pubitemid 35462767)
2. KL Knutson ML Disis 2005 Tumor antigen-specific T helper cells in cancer immunity and immunotherapy Cancer Immunol Immunother 54 721 728 10.1007/s00262-004-0653-2 16010587 1:CAS:528:DC%2BD2MXmtVajt78%3D (Pubitemid 40977140)
3. H Kobayashi R Omiya M Ruiz E Huarte P Sarobe JJ Lasarte M Herraiz B Sangro J Prieto F Borras-Cuesta E Celis 2002 Identification of an antigenic epitope for helper T lymphocytes from carcinoembryonic antigen Clin Cancer Res 8 3219 3225 12374692 1:CAS:528:DC%2BD38XosFKhsbg%3D
4. G Campi M Crosti G Consogno V Facchinetti BM Conti-Fine R Longhi G Casorati P Dellabona MP Protti 2003 CD4(+) T cells from healthy subjects and colon cancer patients recognize a carcinoembryonic antigen-specific immunodominant epitope Cancer Res 63 8481 8486 14679013 1:CAS:528: DC%2BD3sXpvVaguro%3D
5. KR Kalli CJ Krco LC Hartmann K Goodman MJ Maurer C Yu EM Johnson CL Erskine ML Disis PJ Wettstein JD Fikes M Beebe G Ishioka KL Knutson 2008 An HLA-DR-degenerate epitope pool detects insulin-like growth factor binding protein 2-specific immunity in patients with cancer Cancer Res 68 4893 4901 10.1158/0008-5472.CAN-07-6726 18559537 1:CAS:528:DC%2BD1cXnt1ejtro%3D
6. KL Knutson CJ Krco CL Erskine K Goodman LE Kelemen PJ Wettstein PS Low LC Hartmann KR Kalli 2006 T-cell immunity to the folate receptor alpha is prevalent in women with breast or ovarian cancer J Clin Oncol 24 4254 4261 10.1200/JCO.2006.05.9311 16908932 1:CAS:528:DC%2BD28XhtVGju7vF (Pubitemid 46630782)
7. H Fujita S Senju H Yokomizo H Saya M Ogawa S Matsushita Y Nishimura 1998 Evidence that HLA class II-restricted human CD4+ T cells specific to p53 self peptides respond to p53 proteins of both wild and mutant forms Eur J Immunol 28 305 316 10.1002/(SICI)1521-4141(199801)28:01<305::AID-IMMU305>3.0.CO;2-3 9485210 1:CAS:528:DyaK1cXpvVyhuw%3D%3D (Pubitemid 28048301)
8. H Kobayashi M Wood Y Song E Appella E Celis 2000 Defining promiscuous MHC class II helper T-cell epitopes for the HER2/neu tumor antigen Cancer Res 60 5228 5236 11016652 1:CAS:528:DC%2BD3cXntVamu78%3D
9. H Kobayashi J Lu E Celis 2001 Identification of helper T-cell epitopes that encompass or lie proximal to cytotoxic T-cell epitopes in the gp100 melanoma tumor antigen Cancer Res 61 7577 7584 11606397 1:CAS:528: DC%2BD3MXnvFShtr4%3D
10. E Jager D Jager J Karbach YT Chen G Ritter Y Nagata S Gnjatic E Stockert M Arand LJ Old A Knuth 2000 Identification of NY-ESO-1 epitopes presented by human histocompatibility antigen (HLA)-DRB4*0101-0103 and recognized by CD4(+) T lymphocytes of patients with NY-ESO-1-expressing melanoma J Exp Med 191 625 630 10.1084/jem.191.4.625 10684854 1:CAS:528:DC%2BD3cXhsVKqs7c%3D (Pubitemid 30691415)
11. HM Zarour JM Kirkwood LS Kierstead W Herr V Brusic CL Slingluff Jr J Sidney A Sette WJ Storkus 2000 Melan-A/MART-1(51-73) represents an immunogenic HLA-DR4-restricted epitope recognized by melanoma-reactive CD4(+) T cells Proc Natl Acad Sci USA 97 400 405 10.1073/pnas.97.1.400 10618430 1:CAS:528: DC%2BD3cXjvVGhuw%3D%3D (Pubitemid 30055843)
12. SL Topalian MI Gonzales M Parkhurst YF Li S Southwood A Sette SA Rosenberg PF Robbins 1996 Melanoma-specific CD4+ T cells recognize nonmutated HLA-DR-restricted tyrosinase epitopes J Exp Med 183 1965 1971 10.1084/jem.183.5.1965 8642306 1:CAS:528:DyaK28XjtF2luro%3D (Pubitemid 26158888)
13. ES Kass JW Greiner JA Kantor KY Tsang F Guadagni Z Chen B Clark R De Pascalis J Schlom C Van Waes 2002 Carcinoembryonic antigen as a target for specific antitumor immunotherapy of head and neck cancer Cancer Res 62 5049 5057 12208760 1:CAS:528:DC%2BD38Xmslyks74%3D
14. JW Hodge KY Tsang DJ Poole J Schlom 2003 General keynote: vaccine strategies for the therapy of ovarian cancer Gynecol Oncol 88 S97 S104 10.1006/gyno.2002.6694 12586096 1:CAS:528:DC%2BD3sXhsVWku7s%3D discussion S110-S113
15. F Guadagni M Roselli M Cosimelli A Spila F Cavaliere R Arcuri R D'Alessandro PL Fracasso V Casale A Vecchione CU Casciani JW Greiner J Schlom 1997 Quantitative analysis of CEA expression in colorectal adenocarcinoma and serum: lack of correlation Int J Cancer 72 949 954 10.1002/(SICI)1097- 0215(19970917)72:6<949::AID-IJC5>3.0.CO;2-P 9378556 1:CAS:528: DyaK2sXmsFWltr8%3D (Pubitemid 27433556)
16. C Ordonez RA Screaton C Ilantzis CP Stanners 2000 Human carcinoembryonic antigen functions as a general inhibitor of anoikis Cancer Res 60 3419 3424 10910050 1:CAS:528:DC%2BD3cXkvFChs78%3D
17. RA Screaton LZ Penn CP Stanners 1997 Carcinoembryonic antigen, a human tumor marker, cooperates with Myc and Bcl-2 in cellular transformation J Cell Biol 137 939 952 10.1083/jcb.137.4.939 9151695 1:CAS:528:DyaK2sXjtlelt7o%3D (Pubitemid 27215515)
18. I Kawashima V Tsai S Southwood K Takesako A Sette E Celis 1999 Identification of HLA-A3-restricted cytotoxic T lymphocyte epitopes from carcinoembryonic antigen and HER-2/neu by primary in vitro immunization with peptide-pulsed dendritic cells Cancer Res 59 431 435 9927058 1:CAS:528:DyaK1MXntFOjtQ%3D%3D
19. S Zaremba E Barzaga M Zhu N Soares KY Tsang J Schlom 1997 Identification of an enhancer agonist cytotoxic T lymphocyte peptide from human carcinoembryonic antigen Cancer Res 57 4570 4577 9377571 1:CAS:528: DyaK2sXmslKqtL0%3D
20. I Kawashima SJ Hudson V Tsai S Southwood K Takesako E Appella A Sette E Celis 1998 The multi-epitope approach for immunotherapy for cancer: identification of several CTL epitopes from various tumor-associated antigens expressed on solid epithelial tumors Hum Immunol 59 1 14 10.1016/S0198-8859(97) 00255-3 9544234 1:CAS:528:DyaK1cXhvVyhsLo%3D (Pubitemid 28141258)
21. JL Marshall JL Gulley PM Arlen PK Beetham KY Tsang R Slack JW Hodge S Doren DW Grosenbach J Hwang E Fox L Odogwu S Park D Panicali J Schlom 2005 Phase I study of sequential vaccinations with fowlpox-CEA(6D)-TRICOM alone and sequentially with vaccinia-CEA(6D)-TRICOM, with and without granulocyte- macrophage colony-stimulating factor, in patients with carcinoembryonic antigen-expressing carcinomas J Clin Oncol 23 720 731 10.1200/JCO.2005.10.206 15613691 1:CAS:528:DC%2BD2MXitVKisbY%3D (Pubitemid 46224171)
22. R Bos S van Duikeren T van Hall P Kaaijk R Taubert B Kyewski L Klein CJ Melief R Offringa 2005 Expression of a natural tumor antigen by thymic epithelial cells impairs the tumor-protective CD4+ T-cell repertoire Cancer Res 65 6443 6449 10.1158/0008-5472.CAN-05-0666 16024649 1:CAS:528: DC%2BD2MXmt1egtbo%3D (Pubitemid 40994433)
23. A Sette S Buus E Appella JA Smith R Chesnut C Miles SM Colon HM Grey 1989 Prediction of major histocompatibility complex binding regions of protein antigens by sequence pattern analysis Proc Natl Acad Sci USA 86 3296 3300 10.1073/pnas.86.9.3296 2717617 1:CAS:528:DyaL1MXit12lu7o%3D (Pubitemid 19129598)
24. A Sette S Buus S Colon C Miles HM Grey 1989 Structural analysis of peptides capable of binding to more than one Ia antigen J Immunol 142 35 40 2535860 1:CAS:528:DyaL1MXhtlehsLY%3D
25. KL Knutson K Schiffman ML Disis 2001 Immunization with a HER-2/neu helper peptide vaccine generates HER-2/neu CD8 T-cell immunity in cancer patients J Clin Invest 107 477 484 10.1172/JCI11752 11181647 1:CAS:528:DC%2BD3MXhtlWktb8%3D
26. S Southwood J Sidney A Kondo MF del Guercio E Appella S Hoffman RT Kubo RW Chesnut HM Grey A Sette 1998 Several common HLA-DR types share largely overlapping peptide binding repertoires J Immunol 160 3363 3373 9531296 1:CAS:528:DyaK1cXitFWlsLk%3D
27. J Sidney S Southwood C Oseroff MF del Guercio A Sette HM Grey 2001 Measurement of MHC/peptide interactions by gel filtration Curr Protoc Immunol 18 18.3
28. Marsh GE, Parham P, Barber LD (2000) The HLA facts book. Academic Press, San Diego
29. CC Wilson B Palmer S Southwood J Sidney Y Higashimoto E Appella R Chesnut A Sette BD Livingston 2001 Identification and antigenicity of broadly cross-reactive and conserved human immunodeficiency virus type 1-derived helper T-lymphocyte epitopes J Virol 75 4195 4207 10.1128/JVI.75.9.4195-4207.2001 11287569 1:CAS:528:DC%2BD3MXivFOkt7s%3D (Pubitemid 32410132)
30. S Hammarstrom 1999 The carcinoembryonic antigen (CEA) family: structures, suggested functions and expression in normal and malignant tissues Semin Cancer Biol 9 67 81 10.1006/scbi.1998.0119 10202129 1:CAS:528:DyaK1MXitlSmurY%3D (Pubitemid 29265523)
31. EV Hogdall L Christensen SK Kjaer J Blaakaer I Jarle Christensen S Gayther IJ Jacobs CK Hogdall 2008 Protein expression levels of carcinoembryonic antigen (CEA) in Danish ovarian cancer patients: from the Danish 'MALOVA' ovarian cancer study Pathology 40 487 492 10.1080/00313020802197889 18604735 1:CAS:528:DC%2BD1cXot1KlsL4%3D (Pubitemid 351950896)
32. H Kobayashi E Celis 2008 Peptide epitope identification for tumor-reactive CD4 T cells Curr Opin Immunol 20 221 227 10.1016/j.coi.2008.04. 011 18499419 1:CAS:528:DC%2BD1cXntlSktrs%3D
33. ML Disis KL Knutson K Schiffman K Rinn DG McNeel 2000 Pre-existent immunity to the HER-2/neu oncogenic protein in patients with HER-2/neu overexpressing breast and ovarian cancer Breast Cancer Res Treat 62 245 252 10.1023/A:1006438507898 11072789 1:CAS:528:DC%2BD3cXnvV2qurs%3D (Pubitemid 30804446)
34. ML Disis TA Gooley K Rinn D Davis M Piepkorn MA Cheever KL Knutson K Schiffman 2002 Generation of T-cell immunity to the HER-2/neu protein after active immunization with HER-2/neu peptide-based vaccines J Clin Oncol 20 2624 2632 10.1200/JCO.2002.06.171 12039923 1:CAS:528:DC%2BD38XkvF2mtr8%3D (Pubitemid 34575634)
35. KL Knutson K Schiffman MA Cheever ML Disis 2002 Immunization of cancer patients with a HER-2/neu, HLA-A2 peptide, p369-377, results in short-lived peptide-specific immunity Clin Cancer Res 8 1014 1018 12006513 1:CAS:528:DC%2BD38XksVSqur0%3D
36. MA Morse Y Deng D Coleman S Hull E Kitrell-Fisher S Nair J Schlom ME Ryback HK Lyerly 1999 A Phase I study of active immunotherapy with carcinoembryonic antigen peptide (CAP-1)-pulsed, autologous human cultured dendritic cells in patients with metastatic malignancies expressing carcinoembryonic antigen Clin Cancer Res 5 1331 1338 10389916 1:CAS:528:DyaK1MXkt1Oqurg%3D (Pubitemid 29282936)
37. MR Weihrauch S Ansen E Jurkiewicz C Geisen Z Xia KS Anderson E Gracien M Schmidt B Wittig V Diehl J Wolf H Bohlen LM Nadler 2005 Phase I/II combined chemoimmunotherapy with carcinoembryonic antigen-derived HLA-A2-restricted CAP-1 peptide and irinotecan, 5-fluorouracil, and leucovorin in patients with primary metastatic colorectal cancer Clin Cancer Res 11 5993 6001 10.1158/1078-0432. CCR-05-0018 16115944 1:CAS:528:DC%2BD2MXos1CisL4%3D (Pubitemid 41170331)
38. A Saha SK Chatterjee KA Foon E Celis M Bhattacharya-Chatterjee 2007 Therapy of established tumors in a novel murine model transgenic for human carcinoembryonic antigen and HLA-A2 with a combination of anti-idiotype vaccine and CTL peptides of carcinoembryonic antigen Cancer Res 67 2881 2892 10.1158/0008-5472.CAN-06-3045 17363612 1:CAS:528:DC%2BD2sXivV2ntr4%3D (Pubitemid 46548979)
39. L Shen R Schroers J Hammer XF Huang SY Chen 2004 Identification of a MHC class-II restricted epitope in carcinoembryonic antigen Cancer Immunol Immunother 53 391 403 10.1007/s00262-003-0455-y 14624313 1:CAS:528: DC%2BD2cXisVWhurw%3D (Pubitemid 38657252)
40. E Tassi F Gavazzi L Albarello V Senyukov R Longhi P Dellabona C Doglioni M Braga V Di Carlo MP Protti 2008 Carcinoembryonic antigen-specific but not antiviral CD4+ T cell immunity is impaired in pancreatic carcinoma patients J Immunol 181 6595 6603 18941250 1:CAS:528:DC%2BD1cXht1Krt7%2FM
41. M Ruiz H Kobayashi JJ Lasarte J Prieto F Borras-Cuesta E Celis P Sarobe 2004 Identification and characterization of a T-helper peptide from carcinoembryonic antigen Clin Cancer Res 10 2860 2867 10.1158/1078-0432.CCR-03- 0476 15102695 1:CAS:528:DC%2BD2cXjt1Cluro%3D (Pubitemid 38509166)
42. D Haidopoulos MM Konstadoulakis PT Antonakis DG Alexiou AM Manouras SM Katsaragakis GF Androulakis 2000 Circulating anti-CEA antibodies in the sera of patients with breast cancer Eur J Surg Oncol 26 742 746 10.1053/ejso.2000.0996 11087638 1:STN:280:DC%2BD3M7jvFKntg%3D%3D (Pubitemid 32059830)
43. KL Knutson B Almand Y Dang ML Disis 2004 Neu antigen-negative variants can be generated after neu-specific antibody therapy in neu transgenic mice Cancer Res 64 1146 1151 10.1158/0008-5472.CAN-03-0173 14871850 1:CAS:528:DC%2BD2cXhtFCgtrg%3D (Pubitemid 38176922)